Salivary gland malignancies are rare. The aim of our study was to investigate radiotherapy-related toxicity and clinical outcome in patients treated at our division with postoperative radiotherapy (pRT) for parotid tumors.
Methods and study design
Forty-three consecutive patients (32 with primary parotid tumors, 9 with parotid metastases and 2 with recurrent benign diseases) were retrospectively analyzed.
Results
The median follow-up was 28 months. Twenty and 5 patients had a follow-up longer than 2 and 5 years, respectively. Thirty-seven patients were alive and most of them (78%) were free from disease. The local and distant control rates were higher in patients with primary parotid tumors (94% and 87.5%) than in patients with parotid metastases (87.5% and 75%). Grade 3 radiotherapy-related acute toxicity of skin and mucosa was recorded in 20.9% and 28% of patients, respectively. Two patients (4.7%) had grade 4 skin toxicity. Late toxicity data were available for 33 (77%) patients. None of the patients developed severe (grade 3 and 4) late toxicity of soft tissues, skin or temporomandibular joints.
Conclusions
Postoperative radiotherapy is a feasible treatment that was found to be effective mainly in patients with primary parotid tumors. Toxicity was acceptable but could probably be further reduced using more advanced radiotherapy techniques. Longer follow-up is required to achieve definitive results.
ChandanaS.R., ConleyB.A.: Salivary gland cancers: current treatments, molecular characteristics and new therapies.Expert Rev Anticancer Ther, 8: 645–652, 2008.
2.
ArmstrongJ.G., HarrisonL., SprioR.H., FassD.E., StrongE.W., FuksZ.Y.: Malignant tumors of major sarlivary gland origin: a matched pair analysis of the role of combined surgery and postoperative radiotherapy.Arch Otolaryngol Head Neck Surg, 116: 290–293, 1990.
3.
BouyonA., HansS., DubuxC., HoussetM.: Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?Cancer Radiotherapy, 11: 465–475, 2007.
4.
GardenA.S., El NaggerA.K., MorrisonW.H., CallenderD.L., King AngK., PetersL.J.: Postoperative radiotherapy for malignant tumors of the parotid gland.Int J Radiat Oncol Biol Phys, 37: 79–85, 1997.
5.
ChenA.M., GranchiP.J., GarciaJ., BucciK.M., FuK.K., EiseleD.W.: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands; implications for adjuvant therapy.Int J Radiat Oncol Biol Phys, 67: 982–987, 2007.
6.
Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van den Ende PL, Burgale F; Dutch Head and Neck Oncology Cooperative Group:The role of radiotherapy in the treatment of malignant salivary gland tumors.Int J Radiat Oncol Biol Phys, 61: 103–111, 2005.
International Commission on Radiation Units and Measurements:Prescribing, recording and reporting photon beam therapy. ICRU report 62. Bethesda, Maryland, USA, 1999.
10.
CoxJ.D., StetsJ., PajakT.F.: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.
11.
SelvinS.: Modern applied biostatistical methods using S-PLUS.Oxford University Press, Oxford, 1998.
12.
ColletD.: Modelling survival data in medical research, Chapman & Hall, London, 1994.
13.
SpiroR.H.: Salivary neoplasms: overview of a 30-year experience with 2,807 patients.Head Neck Surg, 8: 177–184, 1986.
14.
NorthC.A., LeeD.J., PiantoadosiS., ZahurakM., JohnsM.E.: Carcinoma of the major salivary glands treated by surgery and postoperative radiotherapy.Int J Radiat Oncol Biol Phys, 18: 1319–1326, 1990.
RenehanA.G., GleaveE.N., SlevinN.J., McGurkM.: Clinico-pathological and treatment related factors influencing survival in parotid cancer.Br J Cancer, 80: 1296–1300, 1999.
17.
LicitraL., MarchiniS., SpinazzéS., RossiA., RoccaA., GrandiC., MolinariR.: Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients.Cancer, 68: 1874–1877, 1991.
18.
JonesA.S., PhillipsD.E., CookJ.A., HelliwellT.R.: A randomised phase II trial of epirubicin and 5-fluorouracil versus cis-platinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.Br J Cancer, 37: 112–114, 1993.
19.
RizkS., RobertA., VandenhooftA., AiroldiM., KornekG., MachielsJ.P.: Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature.Eur Arch Otorhinolaryngol, 264: 587–594, 2007.
20.
SurakantiS.G., AgulnikM.: Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.Sem Oncol, 35: 309–319, 2008.
21.
YaparpalviR., FontenlaD.P., TyerechS.K., BoselliL.R., BeitlerJ.: Parotid gland tumors; a comparison of postoperative radiotherapy techniques using three dimensional (3D) dose distributions and dose-volume histograms (DVHs).Int J Radiat Oncol Biol Phys;40: 43–49, 1998.
GurneyT.A., EiseleD.W., WeinbergW., ShinE., LeeN.: Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation.Laryngoscope, 115: 1278–1282, 2005.
24.
BhideS., HarringtonJK, NuttingC.M.: Otological toxicity after postoperative radiotherapy for parotid tumors.Clin Oncol (R Coll Radiol), 19: 77–82, 2007.
25.
NuttingC.M., RowbottomC.G., CosgroveV.P., HenkJ.M., DearnaleyD.P., RobinsonM.H., ConwayJ., WebbS.: Optimization of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity modulated techniques.Radiother Oncol, 60: 163–172, 2001.
26.
Lamers-KuijperE., SchwarzM., RaschC., MijnheerB.: Intensity modulated vs. conformal radiotherapy of parotid gland tumors: potential impact on hearing loss.Med Dosim, 32: 237–245, 2007.
27.
BraggC.M., ConwayJ., RobinsonM.H.: The role of intensity-modulated radiotherapy in the treatment of patotid tumors.Int J Radiat Oncol Biol Phys, 52: 729–738, 2002.
28.
RowbottomC.G., NottingC.M., WebbS.: Beam-orientation optimization of intensity modulated radiotherapy: clinical application to parotid gland tumors.Radiother Oncol, 59: 169–177, 2001.
29.
Jereczek-FossaB.A., KrengliM., OrecchiaR.: Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience.Head Neck, 28: 750–760, 2006.
30.
GriffinT.W., PajakT.F., LaramoreG.E., DuncanW., RichterM.P., HendricksonF.R., MaorM.H.: Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC cooperative randomized study.Int J Radiat Oncol Biol Phys, 15: 1085–1090, 1988.
31.
LaramoreG.E., KrallJ.M., GriffinTW, DuncanW., RichterM.P., SarojaK.R., MaorM.H., DavisL.W.: Neutron versus photon irradiation for unresectable salivary gland tumors; final report of an RTOG-MRC randomized clinical trial.Int J Radiat Oncol Biol Phys, 27: 235–240, 1993.
32.
KrullA., SchwarzR., BrackrockS., Engenhart-CabillicR., HuberP., ProttF.J., BreteauN., FavreA., LesselA., KoppeH., AubergerT.: Neutron therapy in malignant salivary gland tumors: results of European centers.Recent Results Cancer Res, 150: 88–99, 1998.
